Recombinant PDCD1 (Pembrolizumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA
Hôte: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits PDCD1 (Pembrolizumab Biosimilar)
- PDCD1 (Pembrolizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp PDCD1 (Pembrolizumab Biosimilar) est non-conjugé
-
Application
- ELISA
- Fonction
- Pembrolizumab Biosimilar - Anti-PD1 mAb
- Attributs du produit
- Antibody Type: IgG4
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Classe de qualité
- Research Grade
- Isotype
- IgG4
-
anti-PDCD1 (Pembrolizumab Biosimilar) antibody
Research Grade Reactivité: Humain FACS, ELISA Hôte: Humanized Monoclonal unconjugated Recombinant Antibody
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- 4°C for short term, -20°C for long term
-
- Antigène
- PDCD1 (Pembrolizumab Biosimilar)
- Abstract
- PDCD1 (Pembrolizumab Biosimilar) Produits
- Classe de substances
- Biosimilar
- Sujet
-
Pembrolizumab
Pembrolizumab is a humanized (from mouse) monoclonal antibody that binds to, and blocks PD-1 located on lymphocytes. It is an anticancer medication used in the treatment of melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer (cancer of the bladder and urinary tract) and renal cell carcinoma (kidney cancer).
-
Vous êtes ici:
